1. Home
  2. Sectors
  3. Government and Public Health
  4. IGP services

IGP services

Accelerating cures

ICON’s extensive site and patient network, specialist global workforce and decades of clinical research experience enable us to speed drug development without compromising safety. We can anticipate and mitigate potential delays and adapt in response to emerging data. As a leading provider of early phase development solutions, we have expertise in clinical pharmacology, CMC, biometrics and bioanalysis. Our central and specialty laboratory solutions, medical imaging and cardiac safety services deliver high quality harmonised data to facilitate the efficient and accurate assessment of drug efficacy and safety. 

Vaccine and drug safety

ICON has contributed to 13 FDA and EMA vaccine approvals in the past ten years. Our global site network allows us to conduct trials that include randomised control and placebo groups. We provide the evidence and data necessary to assess the benefits and risks of vaccines and therapies for infectious and chronic diseases. ICON offers comprehensive cardiac monitoring solutions across all therapeutic areas to minimise the risk of adverse events that could compromise participant safety.

  • 200+

    studies conducted

  • 409,000+

    clinical trial participants

  • 5,900 +

    sites worldwide

Leveraging expertise in chronic disease

ICON’s therapeutic and cross-therapeutic experts have experience across a range of chronic diseases including obesity, oncology, and mental health conditions such as post-traumatic stress disorder (PTSD) and major depressive disorder (MDD). In our specialised Centres for Obesity, Rare Diseases and Neurosciences, leading scientists and professionals collaborate to develop innovative treatments for these serious health conditions.

Commitment to pediatrics and women’s health

We have experience developing therapeutics, vaccines and medical devices in pediatrics and women’s health. Our pediatric experts have contributed to the approval of 21 pediatric medicinal products. In the past 5 years ICON participated in 421 Phase 1-4 clinical studies involving pediatric participants. ICON also has extensive experience in women’s health, conducting more than 184 studies involving 64,700+ participants.

Real world solutions

Clinical trial tokenisation enables ICON to follow patients both before trial and for up to 15 years afterwards to assess long-term drug and vaccine safety. Our range of digital health technologies make it easier for participants to report changes in their health outcomes remotely. Updates of changes are sent to sites in near real-time, improving the safety and accessibility of trials.

Harnessing big data

Through Symphony Health, an ICON plc company, we provide access to patient insights that aid clinical development across all clinical development phases. These insights can be drawn from either open or closed claims datasets or a combination of both types of datasets.

  • 305m+

    patients

  • 40b+

    healthcare transactions processed annually

  • 2.3m+

    active prescribers

  • 98%

    healthcare transactions with an identified payer, plan or PBM

Optimising trials with AI

ICON’s AI products contribute to designing more efficient and cost-effective studies bringing more affordable treatments to patients sooner. A range of AI tools automate repetitive tasks, identify suitable study site locations and source qualified key opinion leaders (KOLs). This helps speed drug development, cuts administrative burden, thereby reducing delays and associated costs.

Decentralised clinical trials

Decentralised clinical trials put the patient at the centre of the trial design to improve participant recruitment, retention and representative inclusion. ICON’s In-Home Services and digital health technologies monitor trial participants’ health where they are, removing participation barriers for rural and hard-to-reach participants.

Public Health

Insights on disease prevention and control, health promotion and education, environmental health and health equity and social justice.

More